Skip to content 
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium. more
| Dec '22 | Dec '23 | Dec '24 | ||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Cost of Revenue | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Gross Profit | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Gross Margin | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Operating Expenses | 22.63M | 31.19M | 48.02M | [{"date":"2022-12-31","value":47.13,"profit":true},{"date":"2023-12-31","value":64.95,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | ||
| Operating Income | (22.63M) | (31.19M) | (48.02M) | [{"date":"2022-12-31","value":-2263400000,"profit":false},{"date":"2023-12-31","value":-3119000000,"profit":false},{"date":"2024-12-31","value":-4802100000,"profit":false}] | ||
| Total Non-Operating Income/Expense | 11.83M | 19.18M | 1.76M | [{"date":"2022-12-31","value":61.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":9.17,"profit":true}] | ||
| Pre-Tax Income | (10.81M) | (12.01M) | (46.26M) | [{"date":"2022-12-31","value":-1080600000,"profit":false},{"date":"2023-12-31","value":-1200900000,"profit":false},{"date":"2024-12-31","value":-4626300000,"profit":false}] | ||
| Income Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income After Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income From Continuous Operations | (8.14M) | (11.39M) | (46.27M) | [{"date":"2022-12-31","value":-814200000,"profit":false},{"date":"2023-12-31","value":-1139000000,"profit":false},{"date":"2024-12-31","value":-4626700000,"profit":false}] | ||
| Income From Discontinued Operations | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Net Income | (8.14M) | (11.39M) | (46.27M) | [{"date":"2022-12-31","value":-814200000,"profit":false},{"date":"2023-12-31","value":-1139000000,"profit":false},{"date":"2024-12-31","value":-4626700000,"profit":false}] | ||
| EPS (Diluted) | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
| AGMB | |
|---|---|
| Current Ratio | 13.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AGMB | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AGMB | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AGMB | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
AgomAb Therapeutics NV American Depositary Shares (AGMB) share price today is $15.386
Yes, Indians can buy shares of AgomAb Therapeutics NV American Depositary Shares (AGMB) on Vested. To buy
Yes, you can purchase fractional shares of AgomAb Therapeutics NV American Depositary Shares (AGMB) via the Vested app. You can start investing in AgomAb Therapeutics NV American Depositary Shares (AGMB) with a minimum investment of $1.
You can invest in shares of AgomAb Therapeutics NV American Depositary Shares (AGMB) via Vested in three simple steps:
The 52-week high price of AgomAb Therapeutics NV American Depositary Shares (AGMB) is $16.65. The 52-week low price of AgomAb Therapeutics NV American Depositary Shares (AGMB) is $12.66.
The price-to-earnings (P/E) ratio of AgomAb Therapeutics NV American Depositary Shares (AGMB) is
The price-to-book (P/B) ratio of AgomAb Therapeutics NV American Depositary Shares (AGMB) is 0.00
The dividend yield of AgomAb Therapeutics NV American Depositary Shares (AGMB) is 0.00%
The market capitalization of AgomAb Therapeutics NV American Depositary Shares (AGMB) is $760.78M
The stock symbol (or ticker) of AgomAb Therapeutics NV American Depositary Shares is AGMB
Consider the share price of AgomAb Therapeutics NV American Depositary Shares as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether AgomAb Therapeutics NV American Depositary Shares has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in AgomAb Therapeutics NV American Depositary Shares shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the AgomAb Therapeutics NV American Depositary Shares stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of AgomAb Therapeutics NV American Depositary Shares and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that AgomAb Therapeutics NV American Depositary Shares stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
